RavenQuest Provides Shareholder Update
August 07 2019 - 5:00AM
RavenQuest BioMed Inc. (the “Company” or “RavenQuest”) –
(CSE: RQB OTCQB: RVVQF Frankfurt: 1IT), one of
Canada’s most innovative cannabis companies, provides the following
update on recent developments.
Product Testing
After the inaugural harvest at our Edmonton
facility, Orbital Gardens have now successfully produced six
cultivars including Brooklyn Sunrise, The Ultimate, CBD Compassion,
CBD Kush, Charlottes Angel and CBD Skunk Haze. All of these
cultivars passed analytical tests otherwise known as the COA
(Certificate of Analysis) as required by Health Canada and came
back with no detected pesticides or Aflatoxins, a reading that is
exceedingly rare thus far from Canadian licensed producers.
We are very excited to see the low microbial readings which serve
as further evidence that we have a repeatable and safe
product. Also the microbial counts indicate that our facility
cleanliness is pristine and the airflow inside the Orbital Gardens
is doing its job.
Health Canada Inspections
Both of our two ultra-modern grow facilities in
Markham and Edmonton were recently visited by Health Canada
inspectors. Inspectors were on site for two days at each facility
and Health Canada found no major issues at either.
Health Canada did spend additional time
reviewing the Edmonton facility with a particular focus on the
Company’s main technological innovations, namely Orbital Gardens
and Harter pharmaceutical dryers. Health Canada found no issues
with the Orbital Gardens or our drying technology.
Supply Agreement
RavenQuest continues to ship product to Wayland
Group, and we continue to maintain an open and transparent dialogue
with them during their transitional period. RavenQuest also
continues to negotiate supply deals with other parties including -
but not limited to - several provincial wholesalers and export
markets. These discussions are prudent with a view toward
customer diversification and have no bearing on shipments to the
Wayland Group.
Summary
After a thorough Health Canada review of our
cannabis production processes, particularly with the Orbital
Gardens at our Edmonton facility, it’s clear that the process is
working, producing an extremely clean and safe end-product and
passing compliance. This is an important and timely
validation of RavenQuest’s production facilities, particularly in
the wake of recent compliance violations by major industry
participants.
Of equal importance is the proof of concept from
RavenQuest’s revolutionary Orbital Garden technology. Our
Company has now successfully taken the technology from a concept,
through engineering, into a built facility, then to successfully
producing some of the cleanest cannabis industry wide, in under 24
months.
Now that our concept has been proven, passed all
lab testing and scrutiny of Health Canada, the next steps will be
to rapidly scale up production at Edmonton and simultaneously move
our European expansion plans forward.
About RavenQuest BioMed Inc.
RavenQuest BioMed Inc. is a diversified publicly
traded cannabis company with divisions focused upon cannabis
production, management services & consulting and specialized
research & development.
On Behalf of the Board of Directors
of RAVENQUEST BIOMED INC.
“George Robinson”Chief Executive Officer
For further information, please contact:Mathieu
McDonald, Corporate Communications – 604-484-1230
Neither Canadian Securities Exchange nor its
Regulation Services Provider (as that term is defined in the
policies of the Canadian Securities Exchange) accepts
responsibility for the adequacy or accuracy of this press release,
which has been prepared by management.
Cautionary Note Regarding Forward-Looking
Statements
All statements in this press release, other than
statements of historical fact, are "forward-looking information"
with respect to the Company within the meaning of applicable
securities laws, including statements with respect to the
production of cannabis from the Company’s facilities, and plans for
further expansion. The Company provides forward-looking statements
for the purpose of conveying information about current expectations
and plans relating to the future and readers are cautioned that
such statements may not be appropriate for other purposes. By its
nature, this information is subject to inherent risks and
uncertainties that may be general or specific and which give rise
to the possibility that expectations, forecasts, predictions,
projections or conclusions will not prove to be accurate, that
assumptions may not be correct and that objectives, strategic goals
and priorities will not be achieved. These risks and uncertainties
include but are not limited to those identified and reported in the
Company’s public filings under the Company’s SEDAR profile at
www.sedar.com. Although the Company has attempted to identify
important factors that could cause actual actions, events or
results to differ materially from those described in
forward-looking information, there may be other factors that cause
actions, events or results not to be as anticipated, estimated or
intended. There can be no assurance that such information will
prove to be accurate as actual results and future events could
differ materially from those anticipated in such statements. The
Company disclaims any intention or obligation to update or revise
any forward-looking information, whether as a result of new
information, future events or otherwise unless required by law.
RavenQuest BioMed (CSE:RQB)
Historical Stock Chart
From Nov 2024 to Dec 2024
RavenQuest BioMed (CSE:RQB)
Historical Stock Chart
From Dec 2023 to Dec 2024